相关实验视频

Updated: Jan 17, 2026

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Published on: January 19, 2010

卢克索利提尼布通过抑制STAT1酸化和减少MDSC透来缓解DSS诱导的急性性结肠炎

Lu Xu¹, Fangyue Xu², Qinghua Yao³

¹Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.

Frontiers in pharmacology

|September 15, 2025

概括

鲁克索利提尼布通过减少炎症和调节免疫细胞,有效治疗小鼠急性结肠炎. 这种JAK1/2抑制剂通过向JAK/STAT1通路,对性结肠炎 (UC) 有希望.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

急性结肠炎是一个重要的健康问题.
性结肠炎 (UC) 需要有效的治疗策略.

研究的目的:

评估Ruxolitinib对小鼠DSS诱导的急性结肠炎的治疗作用.
为了研究鲁克索利提尼布对疾病活动,炎症,髓质衍生抑制细胞 (MDSC) 和JAK/STAT1通路的影响.

主要方法:

在C57BL/6小鼠中的DSS诱导的急性结肠炎模型.
用鲁克索利提尼布 (30毫克/公斤) 治疗14天.
临床参数的评估,MDSCs的流细胞计,以及JAK-STAT通路基因的分子分析 (PCR阵列,EMSA,西部斑).

主要成果:

鲁克索利提尼布显著缓解了结肠炎症状,包括减轻体重减轻和改善结肠长度.
卢克索利提尼布治疗降低了血液中髓质衍生抑制细胞 (MDSCs) 的比例.
卢克索利替尼抑制了STAT1激活和酸化,降低了JAK-STAT通路基因转录的调节.

结论:

鲁克索利提尼布通过减少炎症和调节MDSCs有效地改善DSS诱导的急性结肠炎.
鲁克索利提尼布对STAT1激活的抑制表明它在UC中起着治疗作用.
鲁克索利提尼布是一种潜在的UC治疗剂,向免疫反应和JAK/STAT1通路.

关键词:

在 DSS 中使用 DSS.在STAT1酸化中.严重的性结肠炎.骨髓系衍生抑制细胞 (MDSCs) 是一种卢克索利提尼布 (Ruxolitinib) 是一种药物.

更多相关视频

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...